Breast cancer is the most commonly diagnosed cancer in women worldwide. Over the past decade, the treatment paradigm for patients with metastatic breast cancer (MBC) has taken an important shift towards better survival and improved quality of life (QOL), especially for those with hormone receptor (HR)-positive diseases which represent the majority of breast cancer subtypes. The introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in the upfront therapy of such patients has resulted in dramatic improvement in progression-free survival (PFS) and overall survival (OS), too. However, almost all patients would, sooner or later, develop disease progression and necessitate transition to different lines of treatment that may include chemotherapy. The idea of maintaining CDK4/6 inhibitors beyond disease progression seems attractive, as this approach has the potential to improve outcome in this setting despite the fact that the true benefit, in terms of survival, might not carry the same weight as it initially does. Researchers have been investigating potential mechanisms of resistance and identify possible biological markers for response after disease progression. Much of the available data is retrospective; however, few randomized clinical trials were recently published and few more are ongoing, addressing this point. In this paper, we intend to review the available published studies investigating the potential role for keeping CDK4/6 inhibitors in play beyond disease progression.
机构:
UCONN Hlth, Dept Med Hematol Oncol, Carole & Ray Neag Comprehens Canc Ctr, Farmington, CT USAUCONN Hlth, Dept Med Hematol Oncol, Carole & Ray Neag Comprehens Canc Ctr, Farmington, CT USA
Alvarez, Alvaro
Bernal, Ana M. M.
论文数: 0引用数: 0
h-index: 0
机构:
Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med Oncol, 1695 Eastchester Rd, Bronx, NY 10461 USAUCONN Hlth, Dept Med Hematol Oncol, Carole & Ray Neag Comprehens Canc Ctr, Farmington, CT USA
Bernal, Ana M. M.
Anampa, Jesus
论文数: 0引用数: 0
h-index: 0
机构:
Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med Oncol, 1695 Eastchester Rd, Bronx, NY 10461 USAUCONN Hlth, Dept Med Hematol Oncol, Carole & Ray Neag Comprehens Canc Ctr, Farmington, CT USA
机构:
Harvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Dept Med Oncol, Boston, MA 02114 USAHarvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Dept Med Oncol, Boston, MA 02114 USA
Spring, Laura M.
Wander, Seth A.
论文数: 0引用数: 0
h-index: 0
机构:
Harvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Dept Med Oncol, Boston, MA 02114 USAHarvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Dept Med Oncol, Boston, MA 02114 USA
Wander, Seth A.
Andre, Fabrice
论文数: 0引用数: 0
h-index: 0
机构:
Inst Gustave Roussy, Dept Med Oncol, Villejuif, FranceHarvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Dept Med Oncol, Boston, MA 02114 USA
Andre, Fabrice
Moy, Beverly
论文数: 0引用数: 0
h-index: 0
机构:
Harvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Dept Med Oncol, Boston, MA 02114 USAHarvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Dept Med Oncol, Boston, MA 02114 USA
Moy, Beverly
Turner, Nicholas C.
论文数: 0引用数: 0
h-index: 0
机构:
Royal Marsden Hosp, Inst Canc Res, Dept Med Oncol, London, EnglandHarvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Dept Med Oncol, Boston, MA 02114 USA
Turner, Nicholas C.
Bardia, Aditya
论文数: 0引用数: 0
h-index: 0
机构:
Harvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Dept Med Oncol, Boston, MA 02114 USAHarvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Dept Med Oncol, Boston, MA 02114 USA